{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:57:04Z","timestamp":1790834224869,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,22]],"date-time":"2016-10-22T00:00:00Z","timestamp":1477094400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12872-016-0361-9","type":"journal-article","created":{"date-parts":[[2016,10,22]],"date-time":"2016-10-22T10:50:34Z","timestamp":1477133434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study"],"prefix":"10.1186","volume":"16","author":[{"given":"Y.","family":"Huo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z. C.","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X. F.","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z. X.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. C.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q. S.","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. X.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. P.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,22]]},"reference":[{"key":"361_CR1","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1183\/09031936.00139009","volume":"34","author":"N Gali\u00e8","year":"2009","unstructured":"Gali\u00e8 N, Hoeper M, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34:1219\u201363.","journal-title":"Eur Respir J"},{"key":"361_CR2","first-page":"825","volume":"10","author":"F Baldi","year":"2014","unstructured":"Baldi F, Fuso L, Arrighi E, Valente S. Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course. Ther Clin Risk Manag. 2014;10:825\u201339.","journal-title":"Ther Clin Risk Manag"},{"key":"361_CR3","unstructured":"Mandras SA, Gilkin RJ, Pruett JA. Pulmonary arterial hypertension: progress and challenges in the modern treatment era. Am J Manag Care. 2014;20(9 Suppl):S191\u20139."},{"key":"361_CR4","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","volume":"40","author":"O Sitbon","year":"2002","unstructured":"Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"361_CR5","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","volume":"106","author":"VV McLaughlin","year":"2002","unstructured":"McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106:1477\u201382.","journal-title":"Circulation"},{"key":"361_CR6","first-page":"401","volume":"7","author":"SM Elshaboury","year":"2013","unstructured":"Elshaboury SM, Anderson JR. Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes. Patient Prefer Adherence. 2013;7:401\u20139.","journal-title":"Patient Prefer Adherence"},{"key":"361_CR7","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","volume":"117","author":"N Gali\u00e8","year":"2008","unstructured":"Gali\u00e8 N, Horst O, Ronald J, Fernando Torres O, Adaani F, Hossein A, et al. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation. 2008;117:3010\u20139.","journal-title":"Circulation"},{"issue":"21","key":"361_CR8","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","volume":"54","author":"R Oudiz","year":"2009","unstructured":"Oudiz R, Gali\u00e8 N, Olschewski H, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Harrison BC, Despain D, Dufton C, Rubin LJ, ARIES Study Group. Long-term Ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(21):1971\u201381.","journal-title":"J Am Coll Cardiol"},{"key":"361_CR9","unstructured":"LETAIRIS\u00ae prescribing information, revised on 2015 \n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/022081s033lbl.pdf\n                    \n                  ."},{"issue":"10 Suppl","key":"361_CR10","first-page":"1","volume":"94","author":"VJ Burroughs","year":"2002","unstructured":"Burroughs VJ, Maxey RW, et al. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc. 2002;94(10 Suppl):1\u201326.","journal-title":"J Natl Med Assoc"},{"key":"361_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","volume":"166","author":"ATS Statement","year":"2002","unstructured":"ATS Statement. Guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"361_CR12","unstructured":"Jing Z. 2006 Six minute walk test in clinical practice Chin J Cardiol. 2006;34(4):183\u2013187."},{"key":"361_CR13","unstructured":"Bosworth. Perspectives on Pulmonary Arterial Hypertension (PAH) - Reviews from published literature. 2014. \n                    http:\/\/www.mednet.ca\/en\/report\/perspectives-on-pulmonary-arterial-hypertension-.html\n                    \n                   (viewed on 2 January 2015)."},{"key":"361_CR14","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2147\/VHRM.S4713","volume":"5","author":"CJ Valerio","year":"2009","unstructured":"Valerio CJ, Coghlan JG. Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. Vasc Health Risk Manag. 2009;5:607\u201319.","journal-title":"Vasc Health Risk Manag"},{"issue":"4","key":"361_CR15","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1183\/09031936.00095606","volume":"29","author":"KG Blyth","year":"2007","unstructured":"Blyth KG, Groenning BA, Mark PB, Martin TN, Foster JE, Steedman T, Morton JJ, Dargie HJ, Peacock AJ. NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J. 2007;29(4):737\u201344. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17135228\n                    \n                  .","journal-title":"Eur Respir J"},{"issue":"123","key":"361_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1183\/09059180.00009011","volume":"21","author":"J-L Vachi\u00e9ry","year":"2012","unstructured":"Vachi\u00e9ry J-L, Yerly P, Huez S. How to detect disease progression in pulmonary arterial hypertension. Eur Respir Rev. 2012;21(123):40\u20137.","journal-title":"Eur Respir Rev"},{"key":"361_CR17","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ahj.2012.01.023","volume":"163","author":"RP Ramos","year":"2012","unstructured":"Ramos RP, Arakaki JS, Barbosa P, Treptow E, Valois FM, Ferreira EV, Nery LE, Neder JA. Heart rate recovery in pulmonary arterial hypertension: relationship with exercise capacity and prognosis. Am Heart J. 2012;163:580\u20139.","journal-title":"Am Heart J"},{"issue":"3","key":"361_CR18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","volume":"46","author":"N Gali\u00e9","year":"2005","unstructured":"Gali\u00e9 N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46(3):529\u201335.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"361_CR19","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1185\/03007995.2011.605440","volume":"27","author":"S Yoshida","year":"2011","unstructured":"Yoshida S, Shirato K, Shimamura R, Nakahara N, Iwase T, Nakajima H. Efficacy, safety, and pharmacokinetics of Ambrisentan in Japanese adults with pulmonary arterial hypertension. Curr Med Res Opin. 2011;27(9):1827\u201334.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"361_CR20","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1185\/03007995.2012.685930","volume":"28","author":"S Yoshida","year":"2012","unstructured":"Yoshida S, Shirato K, Shimamura R, Iwase T, Aoyagi N, Nakajima H. Long-term safety and efficacy of Ambrisentan in Japanese adults with pulmonary arterial hypertension. Curr Med Res Opin. 2012;28(6):1069\u201376.","journal-title":"Curr Med Res Opin"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-016-0361-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12872-016-0361-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-016-0361-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T19:30:52Z","timestamp":1487705452000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-016-0361-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,22]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["361"],"URL":"https:\/\/doi.org\/10.1186\/s12872-016-0361-9","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,22]]},"article-number":"201"}}